[go: up one dir, main page]

MA38240B1 - Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides - Google Patents

Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides

Info

Publication number
MA38240B1
MA38240B1 MA38240A MA38240A MA38240B1 MA 38240 B1 MA38240 B1 MA 38240B1 MA 38240 A MA38240 A MA 38240A MA 38240 A MA38240 A MA 38240A MA 38240 B1 MA38240 B1 MA 38240B1
Authority
MA
Morocco
Prior art keywords
cancer
treatment
solid tumors
compounds useful
preferably solid
Prior art date
Application number
MA38240A
Other languages
English (en)
Other versions
MA38240A1 (fr
Inventor
Steven Gregory Mischke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38240A1 publication Critical patent/MA38240A1/fr
Publication of MA38240B1 publication Critical patent/MA38240B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)

Abstract

L'invention concerne des composés de formule (i), ou des sels pharmaceutiquement acceptables de ceux-ci, dans cette formule, z, x, q et r1sont tels de décrits dans le descriptif. L'invention concerne également des méthodes consistant à utiliser ces composés pour traiter un cancer.
MA38240A 2012-12-11 2013-12-09 Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides MA38240B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261735684P 2012-12-11 2012-12-11
PCT/EP2013/075874 WO2014090709A1 (fr) 2012-12-11 2013-12-09 Composés dimères

Publications (2)

Publication Number Publication Date
MA38240A1 MA38240A1 (fr) 2018-02-28
MA38240B1 true MA38240B1 (fr) 2018-09-28

Family

ID=49726780

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38240A MA38240B1 (fr) 2012-12-11 2013-12-09 Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides

Country Status (18)

Country Link
US (1) US9409888B2 (fr)
EP (1) EP2931719B1 (fr)
JP (1) JP6309536B2 (fr)
KR (1) KR20150093228A (fr)
CN (1) CN104854100B (fr)
AU (1) AU2013357493A1 (fr)
CA (1) CA2887497A1 (fr)
CL (1) CL2015001374A1 (fr)
CO (1) CO7350640A2 (fr)
CR (1) CR20150211A (fr)
EA (1) EA201591024A1 (fr)
IL (1) IL238968A0 (fr)
MA (1) MA38240B1 (fr)
MX (1) MX2015007053A (fr)
PE (1) PE20151083A1 (fr)
PH (1) PH12015501088A1 (fr)
SG (1) SG11201503718QA (fr)
WO (1) WO2014090709A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014044622A1 (fr) * 2012-09-19 2014-03-27 F. Hoffmann-La Roche Ag 2-oxo-2,3,4,5-tétrahydro-1 h-benzo[b]diazépines et leur utilisation dans le traitement du cancer
JP6680683B2 (ja) * 2013-11-18 2020-04-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ベンゾジアゼピノン類
WO2016079527A1 (fr) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Polythérapie
WO2016097773A1 (fr) 2014-12-19 2016-06-23 Children's Cancer Institute Antagonistes des iap thérapeutiques pour traiter des troubles prolifératifs
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6787331B2 (ja) * 2015-10-02 2020-11-18 日本ゼオン株式会社 酸ハライド溶液の製造方法、混合溶液、及びモノエステル化合物の製造方法
CN109311867A (zh) 2016-04-20 2019-02-05 葛兰素史克知识产权开发有限公司 包含ripk2抑制剂的共轭物
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
WO2021026349A1 (fr) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Polythérapie pour le traitement du cancer
EP4395828A1 (fr) 2021-09-01 2024-07-10 Novartis AG Agents de dégradation bifonctionnels comprenant un liant de tead
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404537B (zh) * 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
CN101861319B (zh) * 2007-11-16 2013-12-11 宇部兴产株式会社 苯并氮杂*酮化合物
WO2009136290A1 (fr) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Pyrrolidines fonctionnalisées et leur utilisation comme inhibiteurs d’iap
WO2011059763A2 (fr) * 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Mimétiques dimères de smac
WO2014044622A1 (fr) * 2012-09-19 2014-03-27 F. Hoffmann-La Roche Ag 2-oxo-2,3,4,5-tétrahydro-1 h-benzo[b]diazépines et leur utilisation dans le traitement du cancer

Also Published As

Publication number Publication date
CA2887497A1 (fr) 2014-06-19
AU2013357493A1 (en) 2015-04-30
CL2015001374A1 (es) 2015-09-25
CR20150211A (es) 2015-05-29
JP2016502986A (ja) 2016-02-01
MX2015007053A (es) 2015-09-28
JP6309536B2 (ja) 2018-04-11
PH12015501088A1 (en) 2015-08-03
CN104854100A (zh) 2015-08-19
SG11201503718QA (en) 2015-06-29
EA201591024A1 (ru) 2015-09-30
US9409888B2 (en) 2016-08-09
WO2014090709A1 (fr) 2014-06-19
MA38240A1 (fr) 2018-02-28
EP2931719A1 (fr) 2015-10-21
HK1213543A1 (zh) 2016-07-08
KR20150093228A (ko) 2015-08-17
IL238968A0 (en) 2015-07-30
US20160024055A1 (en) 2016-01-28
CN104854100B (zh) 2017-05-24
EP2931719B1 (fr) 2017-01-25
PE20151083A1 (es) 2015-08-06
CO7350640A2 (es) 2015-08-10

Similar Documents

Publication Publication Date Title
MA38240B1 (fr) Nouveaux composes dimeres substitues antagonistes de l'iap utiles pour le traitement du cancer, de preference des tumeurs solides
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201590748A1 (ru) Противовирусные соединения против rsv
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA39777B1 (fr) Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA40225A (fr) Composés dihydroisoquinolinone substitués
EA201201161A1 (ru) Пирролопиримидины в качестве ингибиторов cdk4/6
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
SV2010003463A (es) Compuestos organicos
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EA201100299A1 (ru) Органические соединения
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
EA201101533A1 (ru) Гетероциклические соединения в качестве ингибиторов mek
UA107455C2 (uk) Похідні індолу як протиракові агенти
EA201791829A1 (ru) Амидные соединения в качестве агонистов рецептора 5-ht
EA201590022A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса